Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis Vol. 51; no. 4; pp. 1107 - 1110
Main Authors: Yin, Shiyu, Huang, Ming, Li, Dengju, Tang, Ning
Format: Journal Article
Language:English
Published: New York Springer US 01.05.2021
Springer Nature B.V
Subjects:
Age Factors
Aged
Anticoagulants
Blood Coagulation Tests - methods
Cardiology
China - epidemiology
Coagulation
Coronaviruses
COVID-19
COVID-19 - blood
COVID-19 - diagnosis
COVID-19 - epidemiology
COVID-19 - physiopathology
Diagnosis, Differential
Female
Fibrin Fibrinogen Degradation Products - analysis
Hematology
Heparin
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Mortality
Organ Dysfunction Scores
Patients
Platelet Count - methods
Platelets
Pneumonia
Pneumonia - blood
Pneumonia - diagnosis
Pneumonia - etiology
Retrospective Studies
Risk Factors
Sepsis - blood
Sepsis - diagnosis
Sepsis - etiology
Severe acute respiratory syndrome coronavirus 2
Sex Factors
Thrombophilia - diagnosis
Thrombophilia - etiology
China
D-dimer
Coronavirus disease 2019
Severe pneumonia
Coagulopathy
ISSN:0929-5305, 1573-742X, 1573-742X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P  = 0.003), COVID group were older (65.1 ± 12.0 vs. 58.4 ± 18.0, years, P  < 0.001) and with higher platelet count (215 ± 100 vs. 188 ± 98, ×10 9 /L, P  = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 μg/mL (32.8% vs. 52.4%, P  = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0929-5305
1573-742X
1573-742X
DOI:10.1007/s11239-020-02105-8